Caryn Parlavecchio Sells 9,035 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Caryn Parlavecchio sold 9,035 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $420,398.55. Following the sale, the insider owned 169,087 shares in the company, valued at $7,867,618.11. This trade represents a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Caryn Parlavecchio also recently made the following trade(s):

• On Friday, January 16th, Caryn Parlavecchio sold 6,600 shares of Scholar Rock stock. The shares were sold at an average price of $44.48, for a total value of $293,568.00.

Scholar Rock Trading Up 1.6%

NASDAQ SRRK traded up $0.74 during trading hours on Thursday, hitting $47.70. 960,100 shares of the company’s stock were exchanged, compared to its average volume of 1,005,770. The business’s 50 day moving average is $45.12 and its 200-day moving average is $38.23. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. Scholar Rock Holding Corporation has a 12-month low of $22.71 and a 12-month high of $49.82. The firm has a market capitalization of $4.87 billion, a P/E ratio of -15.14 and a beta of 0.67.

Wall Street Analyst Weigh In

SRRK has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. JPMorgan Chase & Co. upped their price objective on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. UBS Group initiated coverage on Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price on the stock. Finally, HC Wainwright boosted their price target on Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average price target of $51.14.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently made changes to their positions in the business. IFP Advisors Inc boosted its position in Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Scholar Rock during the fourth quarter worth about $30,000. Summit Securities Group LLC purchased a new stake in shares of Scholar Rock in the fourth quarter worth about $31,000. Ramirez Asset Management Inc. purchased a new stake in shares of Scholar Rock in the third quarter worth about $37,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).